Monte Rosa Therapeutics (GLUE) Competitors $18.81 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$18.80 -0.01 (-0.05%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLUE vs. TGTX, TERN, SRRK, CGON, and PTCTShould you buy Monte Rosa Therapeutics stock or one of its competitors? MarketBeat compares Monte Rosa Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Monte Rosa Therapeutics include TG Therapeutics (TGTX), Terns Pharmaceuticals (TERN), Scholar Rock (SRRK), CG Oncology (CGON), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry. GLUE vs. TGTXGLUE vs. TERNGLUE vs. SRRKGLUE vs. CGONGLUE vs. PTCTHow does Monte Rosa Therapeutics compare to TG Therapeutics?Monte Rosa Therapeutics (NASDAQ:GLUE) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations. Which has stronger valuation & earnings, GLUE or TGTX? TG Therapeutics has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$123.67M12.85-$38.63M-$1.48N/ATG Therapeutics$616.29M9.65$447.18M$2.8613.59 Is GLUE or TGTX more profitable? TG Therapeutics has a net margin of 65.95% compared to Monte Rosa Therapeutics' net margin of -302.69%. TG Therapeutics' return on equity of 88.73% beat Monte Rosa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa Therapeutics-302.69% -40.99% -25.94% TG Therapeutics 65.95%88.73%43.44% Which has more risk & volatility, GLUE or TGTX? Monte Rosa Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market. Does the media favor GLUE or TGTX? In the previous week, Monte Rosa Therapeutics and Monte Rosa Therapeutics both had 3 articles in the media. TG Therapeutics' average media sentiment score of 0.64 beat Monte Rosa Therapeutics' score of 0.00 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TG Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate GLUE or TGTX? Monte Rosa Therapeutics currently has a consensus price target of $32.50, suggesting a potential upside of 72.78%. TG Therapeutics has a consensus price target of $52.50, suggesting a potential upside of 35.07%. Given Monte Rosa Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67TG Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57 Do institutionals and insiders hold more shares of GLUE or TGTX? 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 10.6% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryTG Therapeutics beats Monte Rosa Therapeutics on 11 of the 16 factors compared between the two stocks.How does Monte Rosa Therapeutics compare to Terns Pharmaceuticals?Terns Pharmaceuticals (NASDAQ:TERN) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations. Does the media refer more to TERN or GLUE? In the previous week, Monte Rosa Therapeutics had 2 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 3 mentions for Monte Rosa Therapeutics and 1 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.35 beat Monte Rosa Therapeutics' score of 0.00 indicating that Terns Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Terns Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, TERN or GLUE? Terns Pharmaceuticals has a beta of -0.37, suggesting that its share price is 137% less volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market. Which has higher earnings & valuation, TERN or GLUE? Monte Rosa Therapeutics has higher revenue and earnings than Terns Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTerns PharmaceuticalsN/AN/A-$96.21M-$1.03N/AMonte Rosa Therapeutics$123.67M12.85-$38.63M-$1.48N/A Do insiders and institutionals believe in TERN or GLUE? 98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 1.5% of Terns Pharmaceuticals shares are held by insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer TERN or GLUE? Terns Pharmaceuticals currently has a consensus target price of $55.14, indicating a potential upside of 4.13%. Monte Rosa Therapeutics has a consensus target price of $32.50, indicating a potential upside of 72.78%. Given Monte Rosa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Terns Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terns Pharmaceuticals 1 Sell rating(s) 10 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.27Monte Rosa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is TERN or GLUE more profitable? Terns Pharmaceuticals has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -302.69%. Terns Pharmaceuticals' return on equity of -20.02% beat Monte Rosa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Terns PharmaceuticalsN/A -20.02% -19.37% Monte Rosa Therapeutics -302.69%-40.99%-25.94% SummaryMonte Rosa Therapeutics beats Terns Pharmaceuticals on 9 of the 16 factors compared between the two stocks.How does Monte Rosa Therapeutics compare to Scholar Rock?Monte Rosa Therapeutics (NASDAQ:GLUE) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation. Which has stronger earnings & valuation, GLUE or SRRK? Monte Rosa Therapeutics has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$123.67M12.85-$38.63M-$1.48N/AScholar RockN/AN/A-$377.94M-$3.59N/A Do institutionals & insiders believe in GLUE or SRRK? 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 13.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, GLUE or SRRK? Monte Rosa Therapeutics has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Is GLUE or SRRK more profitable? Scholar Rock has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -302.69%. Monte Rosa Therapeutics' return on equity of -40.99% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa Therapeutics-302.69% -40.99% -25.94% Scholar Rock N/A -163.52%-96.67% Does the media prefer GLUE or SRRK? In the previous week, Monte Rosa Therapeutics and Monte Rosa Therapeutics both had 3 articles in the media. Scholar Rock's average media sentiment score of 0.72 beat Monte Rosa Therapeutics' score of 0.00 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scholar Rock 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend GLUE or SRRK? Monte Rosa Therapeutics currently has a consensus price target of $32.50, indicating a potential upside of 72.78%. Scholar Rock has a consensus price target of $56.00, indicating a potential upside of 16.35%. Given Monte Rosa Therapeutics' higher probable upside, research analysts clearly believe Monte Rosa Therapeutics is more favorable than Scholar Rock.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67Scholar Rock 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 5 Strong Buy rating(s) 3.17 SummaryMonte Rosa Therapeutics beats Scholar Rock on 8 of the 15 factors compared between the two stocks.How does Monte Rosa Therapeutics compare to CG Oncology?Monte Rosa Therapeutics (NASDAQ:GLUE) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment. Which has higher valuation and earnings, GLUE or CGON? Monte Rosa Therapeutics has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$123.67M12.85-$38.63M-$1.48N/ACG Oncology$4.04M1,402.69-$160.99M-$2.33N/A Do institutionals and insiders believe in GLUE or CGON? 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, GLUE or CGON? Monte Rosa Therapeutics has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Does the media favor GLUE or CGON? In the previous week, CG Oncology had 2 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 5 mentions for CG Oncology and 3 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.00 beat CG Oncology's score of -0.08 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CG Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts prefer GLUE or CGON? Monte Rosa Therapeutics presently has a consensus target price of $32.50, indicating a potential upside of 72.78%. CG Oncology has a consensus target price of $81.73, indicating a potential upside of 27.20%. Given Monte Rosa Therapeutics' higher possible upside, equities analysts clearly believe Monte Rosa Therapeutics is more favorable than CG Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67CG Oncology 1 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.71 Is GLUE or CGON more profitable? CG Oncology has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -302.69%. CG Oncology's return on equity of -23.33% beat Monte Rosa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa Therapeutics-302.69% -40.99% -25.94% CG Oncology N/A -23.33%-22.24% SummaryMonte Rosa Therapeutics beats CG Oncology on 9 of the 16 factors compared between the two stocks.How does Monte Rosa Therapeutics compare to PTC Therapeutics?PTC Therapeutics (NASDAQ:PTCT) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation. Do analysts recommend PTCT or GLUE? PTC Therapeutics currently has a consensus price target of $88.36, indicating a potential upside of 28.41%. Monte Rosa Therapeutics has a consensus price target of $32.50, indicating a potential upside of 72.78%. Given Monte Rosa Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 2 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.57Monte Rosa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has stronger earnings & valuation, PTCT or GLUE? PTC Therapeutics has higher revenue and earnings than Monte Rosa Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$1.73B3.30$682.64M-$2.33N/AMonte Rosa Therapeutics$123.67M12.85-$38.63M-$1.48N/A Do insiders and institutionals believe in PTCT or GLUE? 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media favor PTCT or GLUE? In the previous week, PTC Therapeutics had 2 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 5 mentions for PTC Therapeutics and 3 mentions for Monte Rosa Therapeutics. PTC Therapeutics' average media sentiment score of 1.06 beat Monte Rosa Therapeutics' score of 0.00 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is PTCT or GLUE more profitable? PTC Therapeutics has a net margin of -22.58% compared to Monte Rosa Therapeutics' net margin of -302.69%. Monte Rosa Therapeutics' return on equity of -40.99% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics-22.58% -362.45% -6.76% Monte Rosa Therapeutics -302.69%-40.99%-25.94% Which has more risk & volatility, PTCT or GLUE? PTC Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market. SummaryMonte Rosa Therapeutics beats PTC Therapeutics on 9 of the 17 factors compared between the two stocks. Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLUE vs. The Competition ExportMetricMonte Rosa TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.59B$3.37B$6.45B$12.34BDividend YieldN/A2.26%2.76%5.28%P/E Ratio-12.7110.3417.9322.89Price / Sales12.85323.98553.9286.28Price / CashN/A125.1743.4956.67Price / Book3.047.0910.377.14Net Income-$38.63M$24.45M$3.57B$335.98M7 Day Performance4.44%5.45%6.01%3.56%1 Month Performance-4.95%2.43%3.52%2.54%1 Year Performance373.80%62.98%34.13%35.05% Monte Rosa Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLUEMonte Rosa Therapeutics2.0037 of 5 stars$18.81flat$32.50+72.8%+373.8%$1.59B$123.67MN/A90TGTXTG Therapeutics4.3474 of 5 stars$40.12-1.6%$52.50+30.9%+12.4%$6.14B$616.29M14.02290TERNTerns Pharmaceuticals1.6046 of 5 stars$52.95flat$55.14+4.1%+1,653.3%$6.12BN/AN/A40Positive NewsSRRKScholar Rock2.5986 of 5 stars$50.59-1.3%$56.00+10.7%+60.4%$6.09BN/AN/A140CGONCG Oncology2.761 of 5 stars$68.16-2.0%$81.73+19.9%+152.6%$6.01B$4.04MN/A61 Related Companies and Tools Related Companies TGTX Alternatives TERN Alternatives SRRK Alternatives CGON Alternatives PTCT Alternatives CNTA Alternatives BLTE Alternatives COGT Alternatives IMVT Alternatives XENE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLUE) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
